| Literature DB >> 23888258 |
Antonella Savoia1, Simone Landi, Alfonso Baldi.
Abstract
INTRODUCTION: This study describes a pivotal clinical trial of a new minimally invasive mesotherapy technique for facial rejuvenation.Entities:
Keywords: Biorevitalization; Cosmetic dermatology; Facial rejuvenation; Fillers; Mesotherapy; Soft-tissue augmentation
Year: 2013 PMID: 23888258 PMCID: PMC3680640 DOI: 10.1007/s13555-012-0018-2
Source DB: PubMed Journal: Dermatol Ther (Heidelb)
Characteristics of formulation A
| Vitamins | Amino acids | Minerals | Nucleotides | Coenzymes | Others |
|---|---|---|---|---|---|
| Tocopherol | Arginine | Sodium chloride | Adenine | Inositol | Sodium hyaluronate |
| Ubiquinone | Lysine | Cytosine | Acetyl cysteine | Water | |
| Cyanocobalamin | Isoleucine | Glutamine | Polysorbate 20 | ||
| Folic acid | Leucine | Guanine | |||
| Riboflavin | Threonine | ||||
| Pyridoxine HCL | Valine | ||||
| Thiamine HCL | Histidine hydrochloride | ||||
| Nicotinamide | Tyrosine | ||||
| Calcium pantothenate | Phenylalanine | ||||
| Ascorbic acid | Glutamic acid | ||||
| Aspartic acid | |||||
| Asparagine | |||||
| Cysteine | |||||
| Proline | |||||
| Serine | |||||
| Alanine | |||||
| Methionine | |||||
| Glycine | |||||
| Tryptophan |
HCL hydrochloride
Global aesthetic improvement scale
| Degree | Description | |
|---|---|---|
| 1 | Exceptional improvement | Excellent corrective result after a session with the Spherofill device |
| 2 | Very improved patient | Marked improvment of the appearance, but not completely optimal. A touch-up would slightly improve the result |
| 3 | Improved patient | Improvement of the appearance, better compared to the initial condition, but a touch-up is advised |
| 4 | Unaltered patient | The appearance substantially remains the same compared to the original condition |
| 5 | Worsened patient | The appearance has worsened compared to the original condition |
Wrinkle severity rating scale
| Score | Description |
|---|---|
| 1 | Absent |
| 2 | Slight |
| 3 | Moderate |
| 4 | Severe |
| 5 | Extreme |
Fig. 1Example cases of facial rejuvenation in the two different patient groups. a A female patient at the beginning of the treatment (1) and at the end of the treatment with formulation A (2). b A female patient at the beginning of the treatment (1), after one session (2), and at the end of the treatment with formulation B
Characteristics of the patients enrolled in the study
| No. | Sex | Age (years) | Formulation used | Treatment site | GAIS1 | GAIS2 | WSRS0 | WSRS1 | WSRS2 |
|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 52 | A | Face/neck | 1 | 1 | 4 | 3 | 3 |
| 2 | M | 55 | A | Face/neck | 1 | 1 | 3 | 2 | 2 |
| 3 | F | 64 | A | Face/décolleté | 3 | 2 | 5 | 4 | 4 |
| 4 | M | 56 | A | Face/neck/hands | 2 | 2 | 4 | 4 | 3 |
| 5 | F | 53 | A | Face/décolleté | 2 | 1 | 4 | 3 | 2 |
| 6 | M | 60 | A | Face/neck | 4 | 3 | 4 | 3 | 3 |
| 7 | F | 59 | A | Face/neck/hands | 4 | 2 | 4 | 4 | 3 |
| 8 | F | 57 | A | Face/neck/hands | 2 | 1 | 3 | 3 | 2 |
| 9 | F | 58 | A | Face/neck | 3 | 3 | 4 | 4 | 3 |
| 10 | F | 58 | A | Face/décolleté | 2 | 2 | 3 | 3 | 2 |
| 11 | F | 63 | A | Face/décolleté/hands | 1 | 1 | 3 | 2 | 2 |
| 12 | F | 65 | A | Face/neck/hands | 4 | 3 | 5 | 4 | 3 |
| 13 | M | 51 | A | Face/neck | 2 | 2 | 4 | 3 | 3 |
| 14 | F | 54 | A | Face/décolleté/hands | 3 | 2 | 3 | 2 | 2 |
| 15 | F | 53 | A | Face/décolleté/neck | 3 | 3 | 3 | 3 | 2 |
| 16 | F | 56 | A | Face/décolleté/hands | 3 | 3 | 4 | 4 | 3 |
| 17 | F | 57 | A | Face/décolleté | 2 | 2 | 3 | 3 | 2 |
| 18 | F | 62 | A | Face/neck/hands | 2 | 1 | 4 | 4 | 3 |
| 19 | F | 62 | A | Face/décolleté/hands | 2 | 1 | 4 | 4 | 3 |
| 20 | M | 64 | A | Face/neck | 1 | 1 | 5 | 4 | 4 |
| 21 | F | 61 | A | Face/décolleté | 3 | 2 | 5 | 5 | 4 |
| 22 | F | 58 | A | Face/décolleté/neck | 3 | 3 | 3 | 3 | 2 |
| 23 | F | 59 | A | Face/décolleté/neck | 2 | 2 | 3 | 3 | 2 |
| 24 | F | 54 | A | Face/neck/hands | 2 | 1 | 4 | 4 | 3 |
| 25 | F | 52 | A | Face/neck | 2 | 2 | 3 | 2 | 2 |
| 26 | F | 54 | A | Face/décolleté/neck | 4 | 3 | 4 | 4 | 3 |
| 27 | F | 64 | A | Face/décolleté/neck | 3 | 2 | 4 | 4 | 3 |
| 28 | F | 62 | A | Face/décolleté | 2 | 2 | 4 | 4 | 3 |
| 29 | F | 63 | A | Face/décolleté | 3 | 1 | 4 | 3 | 3 |
| 30 | M | 61 | A | Face/neck | 3 | 1 | 3 | 3 | 2 |
| 31 | F | 60 | A | Face/décolleté/neck | 1 | 1 | 4 | 4 | 3 |
| 32 | F | 60 | A | Face/décolleté/neck | 3 | 2 | 3 | 2 | 2 |
| 33 | F | 37 | A | Face/décolleté/neck | 1 | 1 | 2 | 2 | 1 |
| 34 | F | 38 | B | Face/décolleté | 2 | 2 | 2 | 2 | 1 |
| 35 | M | 43 | B | Face/neck | 1 | 1 | 3 | 3 | 2 |
| 36 | F | 50 | B | Face/décolleté | 2 | 2 | 4 | 3 | 3 |
| 37 | F | 36 | B | Face/décolleté/neck | 1 | 1 | 2 | 1 | 1 |
| 38 | F | 35 | B | Face/décolleté/neck | 1 | 1 | 3 | 1 | 1 |
| 39 | F | 47 | B | Face/décolleté/neck | 3 | 2 | 3 | 3 | 2 |
| 40 | F | 42 | B | Face/décolleté/neck | 2 | 2 | 3 | 3 | 2 |
| 41 | F | 47 | B | Face/décolleté | 2 | 1 | 4 | 3 | 3 |
| 42 | M | 39 | B | Face/neck | 1 | 1 | 2 | 2 | 1 |
| 43 | M | 40 | B | Face/neck | 1 | 1 | 2 | 2 | 1 |
| 44 | F | 45 | B | Face/décolleté | 2 | 2 | 3 | 2 | 2 |
| 45 | F | 43 | B | Face/décolleté/neck | 1 | 1 | 3 | 2 | 2 |
| 46 | F | 39 | B | Face/neck | 2 | 1 | 2 | 2 | 1 |
| 47 | F | 45 | B | Face/décolleté/ | 1 | 1 | 4 | 4 | 3 |
| 48 | F | 35 | B | Face/décolleté/neck | 2 | 2 | 3 | 2 | 1 |
| 49 | F | 36 | B | Face/décolleté/neck | 3 | 2 | 2 | 1 | 1 |
| 50 | F | 49 | B | Face/décolleté | 2 | 1 | 4 | 3 | 2 |
GAIS1 after two treatments, GAIS2 after four treatments; significantly different from GAIS1 (P = 0.008), WSRS0 at the beginning of the treatment, WSRS1 after two treatments; significantly different from WSRS0 (P = 0.014), WSRS2 after four treatments; significantly different from WSRS1 (P = 0.002)
Fig. 2Different expression levels of the various proteins analyzed, before (marked as A) and after (marked as B) treatment with formulation A. Asterisks indicate the statistical significance of each expression level. *P = 0.002; **P = 0.011; ***P = 0.001; ****P = 0.0001